Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 1:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 157 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Naltrexone or Placebo Clear all
Completed Phase 4 Interventional

Sertraline for Alcohol Dependence and Depression

NCT00004554
View directory record Official record
Conditions
Alcoholism, Depression
Interventions
naltrexone (Revia), sertraline (Zoloft), Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 65 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 6, 2015 · Synced Oct 2, 2026, 1:35 AM EDT
Completed Phase 4 Interventional

Naltrexone, Craving, and Drinking

NCT00006203
View directory record Official record
Conditions
Alcoholism
Interventions
Naltrexone 50 Mg, Placebo
Drug
Lead sponsor
Brown University
Other
Eligibility
21 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Oct 2, 2026, 1:35 AM EDT
Withdrawn Phase 4 Interventional

Evaluation of Naltrexone as a Treatment for Self-injurious Behavior

NCT02726035
View directory record Official record
Conditions
Self-injurious Behavior, Self Mutilation
Interventions
Naltrexone, Placebo
Drug · Other
Lead sponsor
Western Michigan University School of Medicine
Other
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 2, 2026, 1:35 AM EDT
Completed Not applicable Interventional Results available

Alcohol Pharmacotherapy for HIV+ Prisoners

NCT01077310
View directory record Official record
Conditions
Alcohol Dependence, Problem Drinking, Hazardous Drinking, Human Immunodeficiency Virus, AIDS
Interventions
Vivitrol- Intramuscular naltrexone (depot-formulation), Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 2, 2026, 1:35 AM EDT
Completed Phase 4 Interventional

Naltrexone Treatment for Alcoholic Women

NCT00000448
View directory record Official record
Conditions
Alcoholism, Eating Disorder
Interventions
naltrexone, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2000
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Oct 2, 2026, 1:35 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clinical Trial to Reduce Drinking in Women With HIV

NCT01625091
View directory record Official record
Conditions
HIV Infection
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older · Female only
Enrollment
194 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
2
States / cities
Coral Gables, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 2, 2026, 1:35 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Control of Cognition (Naltrexone, Methylphenidate, and ADHD Study (NMAS))

NCT01993108
View directory record Official record
Conditions
Healthy, Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate, Naltrexone, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 35 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Oct 2, 2026, 1:35 AM EDT
Completed Phase 2 Interventional Results available

Investigation of Naltrexone for Pathological Gambling

NCT01057862
View directory record Official record
Conditions
Pathological Gambling
Interventions
Naltrexone, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
3
States / cities
Middletown, Connecticut • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Oct 2, 2026, 1:35 AM EDT
Completed Phase 2 Interventional Results available

A Study Using Functional Magnetic Resonance Imaging (fMRI) to Assess the Effects of Naltrexone SR/ Bupropion SR Therapy in Overweight or Obese Subjects

NCT00711477
View directory record Official record
Conditions
Obesity
Interventions
Naltrexone SR 32 mg/bupropion SR 360 mg/day, Placebo, fMRI scan
Drug · Other
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Upton, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2015 · Synced Oct 2, 2026, 1:35 AM EDT
Terminated Phase 3 Interventional Results available

Low-Dose Naltrexone in Combination With Standard Treatment in Women With Endometriosis

NCT03970330
View directory record Official record
Conditions
Endometriosis
Interventions
Naltrexone, Norethindrone Acetate, Placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Oct 2, 2026, 1:35 AM EDT
Completed Phase 4 Interventional Results available

Prevention of Stimulant-Induced Euphoria With an Opioid Receptor Antagonist

NCT01673594
View directory record Official record
Conditions
ADHD, Stimulant-Induced Euphoria
Interventions
SODAS MPH, Naltrexone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 30 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Oct 2, 2026, 1:35 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Opioid Modulation and Neural Reward Activation in Healthy Adults

NCT04854551
View directory record Official record
Conditions
Alcohol Drinking, Opioid Use, Unspecified
Interventions
Naltrexone, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 35 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 2, 2026, 1:35 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Combination Gerotherapeutic Interventions for Healthspan Improvement

NCT07475546
View directory record Official record
Conditions
Healthspan Improvement, Aging, Longevity
Interventions
Rapamycin, Naltrexone, Metformin, NAD+, GSH, Infinite Supplement, Placebo/control, B12, Intervention: Guided Meditation Program, Control: Podcast Listening Activity, Control: Standard Exercise Regimen, Intervention: Structured Exercise Program
Drug · Dietary Supplement · Behavioral
Lead sponsor
AgelessRx
Industry
Eligibility
60 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 2, 2026, 1:35 AM EDT
Completed Phase 2 Interventional

Addition of Naltrexone to Methadone Taper

NCT00135759
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders, Substance-Related Disorders
Interventions
naltrexone, Placebo comparator
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 2, 2026, 1:35 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Food Reward in Native American Women

NCT01623440
View directory record Official record
Conditions
Obesity
Interventions
Placebo and fMRI, Naltrexone and fMRI
Combination Product
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 12, 2019 · Synced Oct 2, 2026, 1:35 AM EDT
Terminated Phase 4 Interventional Results available

Naltrexone Treatment for Prolonged Grief Disorder (PGD)

NCT04547985
View directory record Official record
Conditions
Prolonged Grief Disorder
Interventions
Naltrexone HCl 50 MG Oral Tablet, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Oct 2, 2026, 1:35 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Pharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a)

NCT04605081
View directory record Official record
Conditions
Loss-of-Control Eating, Obesity/Overweight
Interventions
Naltrexone and Bupropion (NB) medication, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 2, 2026, 1:35 AM EDT
Completed Phase 2 Interventional

Naltrexone and Clonidine Combination (ATNC05) in the Treatment of Chronic Back Pain

NCT01415895
View directory record Official record
Conditions
Back Pain, Lower Back Pain, Cervical Pain
Interventions
Naltrexone and Clonidine Combination, placebo
Drug
Lead sponsor
Annette C. Toledano MD
Industry
Eligibility
19 Years to 70 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
North Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Oct 2, 2026, 1:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Naltrexone-Bupropion-Methamphetamine Interaction Study

NCT01359930
View directory record Official record
Conditions
Methamphetamine Dependence
Interventions
placebo, Naltrexone and Bupropion SR
Other · Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 2, 2026, 1:35 AM EDT
Completed Phase 3 Interventional Results available

A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain

NCT01571362
View directory record Official record
Conditions
Chronic Pain, Low Back Pain, Analgesia
Interventions
ALO-02, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
52
States / cities
Mobile, Alabama • Goodyear, Arizona • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 2, 2026, 1:35 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy of Naltrexone in Women's Smoking Cessation

NCT00271024
View directory record Official record
Conditions
Smoking, Smoking Cessation
Interventions
Naltrexone (drug), Placebo (for Naltrexone)
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
333 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 2, 2026, 1:35 AM EDT
Completed Phase 2 Interventional Results available

The Effect of Naltrexone and Varenicline on Alcohol-Mediated Smoking Lapse

NCT00773422
View directory record Official record
Conditions
Smoking
Interventions
naltrexone, varenicline, placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Oct 2, 2026, 1:35 AM EDT
Completed Phase 2 Interventional Results available

Naltrexone for Individuals of East Asian Descent

NCT02026011
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 65 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Oct 2, 2026, 1:35 AM EDT
Completed Phase 2 Interventional

Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis

NCT03482479
View directory record Official record
Conditions
Eosinophilic Granulomatosis With Polyangiitis (EGPA), Churg-Strauss Syndrome (CSS), Giant Cell Arteritis, Granulomatosis With Polyangiitis, Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu Arteritis
Interventions
Naltrexone Hydrochloride, Placebo Comparator
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
6
States / cities
Boston, Massachusetts • Rochester, Minnesota • Cleveland, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 2, 2026, 1:35 AM EDT